{
  "pmcid": "11392186",
  "sha256": "81a7ddcc605d72e6143ec6c679c8ce2721cfe6bc74ee24c8397bd87749dc2135",
  "timestamp_utc": "2025-11-09T23:15:48.188478+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 16.498154761904768,
    "reading_ease": -1.0559325396825159,
    "word_count": 224
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Efficacy of Prophylactic Antibiotics in Clean and Clean-Contaminated Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was conducted at the participant level, with allocation concealment ensured."
      },
      "Participants": {
        "score": 2,
        "evidence": "The study setting included various international locations, and eligibility criteria focused on clean and clean-contaminated surgeries."
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing preoperative and postoperative prophylactic antibiotic use against placebo in clean and clean-contaminated surgeries."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of surgical site infections (SSIs), measured over the postoperative period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted at the participant level, with allocation concealment ensured."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The pooled odds ratio (OR) for SSIs with antibiotic prophylaxis versus placebo was 0.60 (95% CI: 0.53â€“0.68)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42023445822."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: No specific funding was received."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}